RxDoctor Payments Data

Stacy Westerman, MD

Clinical Cardiac Electrophysiology · Atlanta, GANPI 1396974960

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 73.0% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $24,173, more than ten times the $369 reported in 2019.

$60,421in general payments, 2019–2025

Across 171 payments — averaging $353.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$44K
  • Medtronic$11K
  • Abbott$5K
  • Biosense Webster, Inc.$142
  • Cardiva Medical, Inc.$54
  • Cardiofocus, Inc.$45
$88,439in research payments, 2019–2025

Across 32 payments — averaging $2763.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$47K
  • Medtronic$41K

What the payments were for

  • Consulting fees$7,18812%
  • Speaking & faculty fees$34,11356%
  • Travel & lodging$11,12618%
  • Food & beverage$7,99413%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific82$44,079
Medtronic(2 entities)29$10,700
Abbott55$5,400
Biosense Webster, Inc.2$142
Cardiva Medical, Inc.2$54
Cardiofocus, Inc.1$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,421 in reported general payments places this provider in the 80th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

See all clinical cardiac electrophysiology providers in Georgia

Medicare billing

Part B allowed, 2024
$328,137
Medicare patients
1,632
Services billed
4,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban723$884,478
XareltoRivaroxaban163$169,416
EntrestoSacubitril/Valsartan12$20,211
Dofetilide74$18,240
FarxigaDapagliflozin Propanediol11$13,015
Flecainide Acetate195$10,409
Metoprolol Succinate383$4,563
Mexiletine Hcl29$3,035
SotalolSotalol Hcl168$2,833
Diltiazem 12hr ErDiltiazem Hcl14$1,989
Amiodarone Hcl87$1,443
Carvedilol113$983
Atorvastatin Calcium144$876
Pravastatin Sodium39$783
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$763

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →